Crohn's & colitis 360
Cure8 research brief
Why This Matters
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate responders from nonresponders where CRP and fecal calprotectin did not.
Who Should Pay Attention
Adult UC patients (especially those considering vedolizumab), clinicians prescribing biologics, and researchers in IBD biomarker development
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This was an observational study of 21 adults treated with standard intravenous VDZ through Week 54; researchers compared baseline and Week 6 serum markers between patients who did or did not reach clinical remission or mucosal healing at Week 14.
Mean LRG levels were lower in patients who achieved remission or mucosal healing, and MCP‑1 was higher at baseline in those who did achieve clinical remission and mucosal healing. Common inflammatory tests (CRP, fecal calprotectin) did not differ between groups in this cohort.
The findings identify serum LRG and MCP‑1 as candidate predictive biomarkers for VDZ response, but the study is small and exploratory. These results point to a possible role for blood-based biomarkers to help predict which UC patients may respond to vedolizumab, warranting validation in larger studies.
Keep In Mind
Small sample size (n=21) and short-term outcome at Week 14; findings are hypothesis-generating and require larger validation studies. Summary is based on the article abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & colitis 360
AuthorsYoshihara T, Shinzaki S, Naka T +6 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.